Introduction: Drug-resistant cluster headache (CH) is still an open clinical challenge. Recently, our group observed the clinical efficacy of a ketogenic diet (KD), usually adopted to treat drug-resistant epilepsies, on migraine. Aim: Here, we aim to detect the effect of KD in a group of drug-resistant chronic CH (CCH) patients. Materials and methods: Eighteen drug-resistant CCH patients underwent a 12-week KD (Modified Atkins Diet, MAD), and the clinical response was evaluated in terms of response (≥50% attack reduction). Results: Of the 18 CCH patients, 15 were considered responders to the diet (11 experienced a full resolution of headache, and 4 had a headache reduction of at least 50% in terms of mean monthly number of attacks during the diet). The mean monthly number of attacks for each patient at the baseline was 108.71 (SD = 81.71); at the end of the third month of diet, it was reduced to 31.44 (SD = 84.61). Conclusion: We observed for the first time that a 3-month ketogenesis ameliorates clinical features of CCH. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03244735.

Di Lorenzo, C., Coppola, G., Di Lenola, D., Evangelista, M., Sirianni, G., Rossi, P., Di Lorenzo, G., Serrao, M., Pierelli, F., Efficacy of Modified Atkins Ketogenic Diet in Chronic Cluster Headache: An Open-Label, Single-Arm, Clinical Trial, <<FRONTIERS IN NEUROLOGY>>, 2018; 9 (64): N/A-N/A. [doi:10.3389/fneur.2018.00064] [http://hdl.handle.net/10807/111024]

Efficacy of Modified Atkins Ketogenic Diet in Chronic Cluster Headache: An Open-Label, Single-Arm, Clinical Trial

Evangelista, Maurizio
Conceptualization
;
Rossi, Paolo;
2018

Abstract

Introduction: Drug-resistant cluster headache (CH) is still an open clinical challenge. Recently, our group observed the clinical efficacy of a ketogenic diet (KD), usually adopted to treat drug-resistant epilepsies, on migraine. Aim: Here, we aim to detect the effect of KD in a group of drug-resistant chronic CH (CCH) patients. Materials and methods: Eighteen drug-resistant CCH patients underwent a 12-week KD (Modified Atkins Diet, MAD), and the clinical response was evaluated in terms of response (≥50% attack reduction). Results: Of the 18 CCH patients, 15 were considered responders to the diet (11 experienced a full resolution of headache, and 4 had a headache reduction of at least 50% in terms of mean monthly number of attacks during the diet). The mean monthly number of attacks for each patient at the baseline was 108.71 (SD = 81.71); at the end of the third month of diet, it was reduced to 31.44 (SD = 84.61). Conclusion: We observed for the first time that a 3-month ketogenesis ameliorates clinical features of CCH. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03244735.
Inglese
Di Lorenzo, C., Coppola, G., Di Lenola, D., Evangelista, M., Sirianni, G., Rossi, P., Di Lorenzo, G., Serrao, M., Pierelli, F., Efficacy of Modified Atkins Ketogenic Diet in Chronic Cluster Headache: An Open-Label, Single-Arm, Clinical Trial, <<FRONTIERS IN NEUROLOGY>>, 2018; 9 (64): N/A-N/A. [doi:10.3389/fneur.2018.00064] [http://hdl.handle.net/10807/111024]
File in questo prodotto:
File Dimensione Formato  
fneur-09-00064.pdf

accesso aperto

Descrizione: ORIGINAL RESEARCH
Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 211.74 kB
Formato Adobe PDF
211.74 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/111024
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact